Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 57Neoplasm Metastasis 21Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Brain Neoplasms 8Colorectal Neoplasms 7Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 3Recurrence 3Neoplasms 3Esophageal Neoplasms 3Adenocarcinoma 3Prostatic Neoplasms 2Meningeal Carcinomatosis 2HER2-positive Gastric Cancer 2Colonic Neoplasms 2Breast Cancer With Brain Metastasis 2Advanced Solid Tumor 2Advanced Breast Cancer 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Overexpression × trastuzumab deruxtecan × 1 year × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡